The position statement from cancer and bone societies updates recommendations from 2017 for managing bone loss and fracture ...

Does race influence long-term outcomes after neoadjuvant chemotherapy in breast cancer: A National Cancer Database analysis. Background: There are currently limited treatment options for patients with ...

However, long-term experience and specific clinical trials have revealed several limitations of tamoxifen in the adjuvant setting, including limited duration of effectiveness, continuing risk of ...

Celcuity (CELC) announced detailed efficacy and safety results from the PIK3CA wild-type cohort of the Phase 3 VIKTORIA-1 clinical trial of ...

A new study has shown that giving aromatase inhibitors instead of tamoxifen to premenopausal women with oestrogen receptor positive (hormone-sensitive) breast cancer significantly reduces the risk of ...

Please provide your email address to receive an email when new articles are posted on . Supportive therapies are necessary to help ensure patients adhere to aromatase inhibitor treatment, according to ...

Breast cancer is the most prevelent cancer in women in the United States, and experts estimate that close to 300,000 cases will be diagnosed in 2022. There are many types of breast cancer, some of ...

Please provide your email address to receive an email when new articles are posted on . Use of an aromatase inhibitor instead of tamoxifen reduced the risk for breast cancer recurrence among ...

Postmenopausal women can use alternative drugs known as aromatase inhibitors, but those are not an option for younger ...